Federal Law - DATA 2000

If you do not have an account: This page is part of a larger Buprenorphine training activity provided by Clinical Tools, Inc. Our DATA 2000/CARA-qualifying Buprenorphine training provides the current information for physicians, nurse practitioners, and physician assistants on prescribing buprenorphine as an office-based treatment for opioid use disorder. Please refer to the Buppractice.com homepage to sign-up and begin the activity!

Current accounts: If you see this message, the system has logged you out because of inactivity. To resume:

  1. Log In
  2. Go To Activity Homepage (Module list page)
  3. Re-Enter Module To Resume Training

There are two major federal laws that, among other provisions, permit the prescribing of buprenorphine in the office-based setting and describe the requirements and limitations:

  • The Drug Addiction Treatment Act (DATA 2000)
  • The Comprehensive Addiction and Recovery Act of 2016 (CARA)
DATA 2000 An Amendment to the Controlled Substances Act

The Drug Addiction Treatment Act (DATA 2000) was an amendment to the Controlled Substances Act signed into law in 2000. DATA made it possible for qualified physicians to prescribe buprenorphine for opioid detoxification and maintenance therapy. PrescribingThe law allowed physicians to be granted a waiver from the special registration requirements of that act, which allows them to prescribe, dispense, or administer buprenorphine to patients in their office, greatly expanding the availability and accessibility of opioid addiction treatment. It also described regulations that govern this prescribing.

The waiver applies to Schedule III, IV, or V medications approved by the FDA for treating opioid use disorder, however, this currently only applies to buprenorphine products (SAMHSA, 2016).

DATA 2000 in Nontraditional Settings: Under DATA 2000, treatment for opioid use disorder can take place in nontraditional settings, such as primary care offices (Pade et al., 2012; Alford et al., 2011; Kahan et al., 2011). An advantage is that, in the past, some patients may have avoided treatment at substance abuse clinics due to worries about stigma and confidentiality.

  • DATA described specific guidelines that physicians must follow before starting to prescribe buprenorphine. These include an 8 hour equivalent training.
  • DATA does not include methadone—only a licensed opioid treatment program can prescribe methadone (DATA, 2000).

Some provisions of the DATA 2000 act were revised by CARA 2016, which is described in the following pages.

View ReferencesHide References
Alford DP, Labelle CT, Kretsch N, Bergeron A, Winter M, Botticelli M, Samet JH. Collaborative care of opioid-addicted patients in primary care using buprenorphine: five-year experience. Archives of Internal Medicine. 2011; 171(5): 425-31. Available at: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3059544/ Accessed on: 2013-10-08.
Fiellin DA, O'Connor PG. New federal initiatives to enhance the medical treatment of opioid dependence. Ann Intern Med. 2002; 137(8): 688-692. Available at: https://www.ncbi.nlm.nih.gov/pubmed/12379070 Accessed on: 2013-10-09.
Kahan M, Srivastava A, Ordean A, Cirone S. Buprenorphine: new treatment of opioid addiction in primary care. Canadian Family Physician. 2011; 57(3): 281-9. Available at: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3056674/ Accessed on: 2013-10-08.
Pade PA, Cardon KE, Hoffman RM, Geppert CM. Prescription opioid abuse, chronic pain, and primary care: a Co-occurring Disorders Clinic in the chronic disease model. J Subst Abuse Treat. 2012; 43(4): 446-50. Available at: http://www.ncbi.nlm.nih.gov/pubmed/22980449 Accessed on: 2014-10-07.
Substance Abuse and Mental Health Services Administration. Sublingual and Transmucosal Buprenorphine for Opioid Use Disorder: Review and Update. Advisory. Winter 2016; 15 (1): . Available at: http://store.samhsa.gov/shin/content//SMA16-4938/SMA16-4938.pdf Accessed on: 2016-03-05.
United States Congress. Drug Addiction Treatment Act of 2000. United States Congress. 2000. Available at: http://www.deadiversion.usdoj.gov/pubs/docs/dwp_buprenorphine.htm Accessed on: 2011-06-29.